Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 982702887
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2012.05.04, US 201261642844 P
AHLERS JEFFREY D ET AL: "A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 99, no. 20, 1 October 2002 (2002-10-01), pages 13020-13025, XP002489213, ISSN: 0027-8424, DOI: 10.1073/PNAS.192251199 (B1)
BERZOFSKY JAY A ET AL: "Progress on new vaccine strategies for the immunotherapy and prevention of cancer", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 11, 1 June 2004 (2004-06-01) , pages 1515-1525, XP002420765, ISSN: 0021-9738, DOI: 10.1172/JCI200421926 (B1)
DATABASE UniProt [Online] 1 June 1994 (1994-06-01), "Glutamate carboxypeptidase 2; EC=3.4.17.21; Cell growth-inhibiting gene 27 protein;Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; FGCP;", XP002713616, retrieved from EBI accession no. UNIPROT:Q04609 Database accession no. Q04609 (B1)
FERRARO BERNADETTE ET AL: "Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.", HUMAN VACCINES 2011 JAN-FEB, vol. 7 Suppl, January 2011 (2011-01), pages 120-127, XP007922265, ISSN: 1554-8619 (B1)
MANGSBO SARA M ET AL: "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 33, no. 3, 1 April 2010 (2010-04-01), pages 225-235, XP009144370, ISSN: 1524-9557 (B1)
YING WAECKERLE-MEN ET AL: "Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 12, 13 April 2006 (2006-04-13), pages 1524-1533, XP019422513, ISSN: 1432-0851, DOI: 10.1007/S00262-006-0157-3 (B1)
R. HOUOT ET AL: "T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy", BLOOD, vol. 113, no. 15, 9 April 2009 (2009-04-09), pages 3546-3552, XP055097924, ISSN: 0006-4971, DOI: 10.1182/blood-2008-07-170274 (B1)
SUTMULLER R P M ET AL: "SYNERGISM OF CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 BLOCKADE AND DEPLETION OF CD25+ REGULATORY T CELLS IN ANTITUMOR THERAPY REVEALS ALTERNATIVE PATHWAYS FOR SUPPRESSION OF AUTOREACTIVE CYTOTOXIC T LYMPHOCYTE RESPONSES", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 194, no. 6, 17 September 2001 (2001-09-17), pages 823-832, XP008040742, ISSN: 0022-1007, DOI: 10.1084/JEM.194.6.823 (B1)
WO-A1-2013/006050 (B1)
WO-A2-2012/065164 (B1)
OLSON WILLIAM C ET AL: "Clinical trials of cancer therapies targeting prostate-specific membrane antigen.", REVIEWS ON RECENT CLINICAL TRIALS SEP 2007, vol. 2, no. 3, September 2007 (2007-09), pages 182-190, XP007922264, ISSN: 1574-8871 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
Patent opphørt | Ikke betalt årsavgift |
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Utgående
EP Opphørt for ikke betalt årsavgift (3206)
|
Utgående
EP Påminnelse om ikke betalt årsavgift (3331) (PTEP2844282)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP2844282)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 9. avg. år (EP) | 2021.03.26 | 2850 | MASTER DATA CENTER INC | Betalt og godkjent |
Årsavgift 8. avg. år (EP) | 2020.02.12 | 2550 | ZACCO NORWAY AS | Betalt og godkjent |
31911645 expand_more expand_less | 2019.07.24 | 5500 | ZACCO NORWAY AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|